AGP-HA Nanoparticles Sensitize Drug-Resistant Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment strategies, particularly chemotherapy, face challenges due to multi-drug resistance (MDR) and metastatic characteristics in breast cancer, where tumor cells develop resistance to chemotherapeutic drugs and exhibit invasive behavior, leading to reduced therapeutic efficacy.
Innovation Solution
Development of hyaluronic acid-chitosan nanoparticles decorated with alpha-1 acid glycoprotein (AGP), which modulates the tumor microenvironment to suppress pro-inflammatory cytokines, turning 'hot' tumors into 'cold' tumors, thereby restoring drug sensitivity and reducing invasiveness, and are used in conjunction with low-dose chemotherapeutic agents to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat breast cancer, then tumor cells are targeted for destruction, but tumor cells develop multi-drug resistance and metastatic characteristics leading to treatment failure
Solution Approach 1:
The nanoparticle system performs preliminary action by suppressing NF-κB signaling and reducing pro-inflammatory cytokines before chemotherapy administration, converting hot tumors into cold tumors to prevent drug resistance development and enhance subsequent chemotherapy efficacy
Solution Approach 2:
The nanoparticle acts as an intermediary carrier that delivers anti-inflammatory agents to the tumor microenvironment, mediating the conversion from inflammatory hot tumors to non-inflammatory cold tumors, thereby sensitizing tumor cells to chemotherapy
2Reliability
If high-dose chemotherapeutic agents are used to overcome drug resistance, then tumor cell killing is enhanced, but toxicity to healthy tissues increases
Solution Approach 1:
The system changes the therapeutic parameter from high-dose chemotherapy to low-dose chemotherapy combined with nanoparticle-mediated anti-inflammatory therapy, achieving enhanced tumor cell killing while reducing toxicity to healthy tissues through modified treatment parameters
Solution Approach 2:
The nanoparticle forms a composite therapeutic system combining anti-inflammatory agents with low-dose chemotherapeutic agents, creating a synergistic effect that enhances tumor cell killing efficacy while minimizing individual drug toxicity
3Productivity
If nanoparticles are used to deliver chemotherapeutic agents, then drug delivery is improved, but the underlying inflammatory tumor microenvironment and metastasis are not addressed
Solution Approach 1:
The nanoparticle system performs multiple functions simultaneously: it delivers chemotherapeutic agents to tumor cells while also suppressing NF-κB signaling and reducing pro-inflammatory cytokines, addressing both drug delivery efficiency and inflammation-induced metastasis prevention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The AGP-decorated nanoparticles effectively inhibit tumor cell proliferation and migration, sensitize drug-resistant breast cancer cells to chemotherapy, and significantly enhance the potency of chemotherapeutic agents like doxorubicin, improving treatment outcomes for metastatic breast cancer.
Implementation Method 1
HA NPs have been reported to exhibit a remarkable feature by adsorbing a unique anti-inflammatory protein alpha-1 acid glycoprotein (AGP) on their surface upon mixing with human serum proteins
Implementation Method 2
soluble AGP can suppress the overexpression of pro-inflammatory cytokines in the tumor microenvironment, including (TNF-α) and interleukins (IL-6) from tumor cells
Data Source
AI summary
An immune-suppressing nanoparticle (NP) decorated with alpha-1 acid glycoprotein (AGP), an anti-inflammatory protein, circumventing the resistance of breast tumor cells to chemotherapy in addition to suppressing the tumor metastasis and invasion is disclosed. Methods of making hyaluronic acid-chitosan nanoparticles decorated with AGP (AGP-HA NPs) by sequential ionic gelation, spray drying, and AGP-surface adsorption are also disclosed. Treatment options to strengthen the anti-cancer effects of chemotherapeutic agents and potentially improve the survival rate of patients with metastatic breast cancer using the disclosed AGP-HA NPs containing agents are also disclosed.